01 The Growth of the Precision Medicine Market is Expected to Be Driven by the Rise of Big Data Analysis and the It Sector It is anticipated that advancements in big data analysis and the information technology industry would result in a reduction in the amount of money and time necessary to produce new precision medications. The creation of novel precision medications will make it easier to provide patients with the appropriate prescription, which in turn will enhance patients' health. Numerous genetic testing and diagnostic tests, which are to be carried out in order to give precision medications, will generate a massive quantity of usable data, which will be necessary for the creation of personalised prescriptions. Because big data analysis and information technology are able to crunch, analyse, and store the required data, it is now possible for doctors to practise precision medicine. The government provides financial support to the primary market participants who are engaged in the process of creating bioinformatics technology for the purposes of precision medicine research applications.
02 Increasing Technological Improvements Are Likely to Boost Market Growth It is anticipated that increasing technological developments, such as the introduction of diagnostic tools that will assist medical professionals in evaluating or carrying out an accurate diagnosis of a disease and, as a result, guiding patients toward the appropriate therapy, will be the primary drivers of market growth over the course of the forecast period.
01 High Cost of Medicine It is anticipated that the high cost of precision medicine, in addition to issues in reimbursement systems, will impede the growth of the industry. The utilisation of high-end calculation methods and advanced computing tools results in the addition of several types of costs to the process of treatment, which is one of the primary reasons why precision medicine is sold at such a high price on the market.
01 Advances in Disease Modeling Modeling could aid in preventing and controlling infectious diseases by estimating the size of epidemics, highlighting the characteristics of disease transmission, assessing the success of treatments or policies, and issuing alerts or forecasts before the onset of diseases. Consumer goods and nanomedicine are only two examples of the many fields where nanomaterials (NMs) are being used more and more. Target tissue dosimetry is crucial in assessing the safety, effectiveness, and potential toxicity of NMs. The necessity for developing strategies to facilitate the efficient creation of safe and effective NMs is growing.A logical progression from well-regulated in vitro experimentation is in silico modeling, in which computer programs are used to create simulations of pharmacologic or physiological processes. It is the inevitable outcome of the research scientist's access to an enormous rise in computing power at steadily declining costs. Thus, making a better interpretation of the disease, thereby making the job easier, can provide opportunities for market expansion.
June 2026 Roche received U.S. FDA approval for the VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic designed to detect PTEN protein loss in prostate adenocarcinoma. The test helps identify patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP in combination with abiraterone.
May 2026 Tempus AI received U.S. FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform. The expanded authorization made Tempus the first laboratory to hold companion diagnostic approvals for both tumor-only and tumor-normal comprehensive genomic profiling approaches.
May 2026 Guardant Health received U.S. FDA approval for a new version of Guardant360 Liquid CDx, significantly expanding the genomic footprint of its liquid-biopsy panel. The test integrates genomic and epigenomic information to provide a broader molecular profile of solid tumors from a blood sample.
December 2025 Foundation Medicine reached 100 approved and active companion diagnostic indications across the U.S. and Japan for its FoundationOne CDx and FoundationOne Liquid CDx platforms. The milestone followed regulatory approval in Japan for using FoundationOne CDx to identify patients with NTRK fusion-positive solid tumors who may benefit from targeted therapy.